Kyverna Therapeutics Inc's stock surged by 18.22% in pre-market trading, reaching a 52-week high. This movement comes as the company prepares to announce topline results from its Phase 2 trial of KYV-101 for stiff person syndrome, a rare autoimmune disorder with limited treatment options.
The stock's rise is attributed to the anticipation surrounding the upcoming results from the KYV-101 trial, which is expected to provide critical data supporting the company's future development plans. Additionally, Kyverna's strategic plans to submit a Biologics License Application (BLA) for miv-cel in 2026 further solidify its position in the CAR T therapy market for autoimmune diseases.
This positive momentum reflects investor confidence in Kyverna's innovative therapies and their potential to address significant unmet medical needs in the autoimmune disease sector.
Wall Street analysts forecast KYTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYTX is 29.50 USD with a low forecast of 20.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast KYTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYTX is 29.50 USD with a low forecast of 20.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.210
Low
20.00
Averages
29.50
High
33.00
Current: 8.210
Low
20.00
Averages
29.50
High
33.00
Wells Fargo
Overweight
maintain
$31 -> $33
2025-12-16
Reason
Wells Fargo
Price Target
$31 -> $33
AI Analysis
2025-12-16
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Kyverna Therapeutics to $33 from $31 and keeps an Overweight rating on the shares. The firm notes that mivocabtagene-autoleucel's stiff person syndrome data is in line with its bull case and it believes shares should trade up into the mid-teens on the data. Wells thinks mivocabtagene-autoleucel could potentially benefit from priority review/CNPV given the high unmet need in stiff person syndrome.
Morgan Stanley
Michael Ulz
Overweight
maintain
$25 -> $33
2025-12-15
Reason
Morgan Stanley
Michael Ulz
Price Target
$25 -> $33
2025-12-15
maintain
Overweight
Reason
Morgan Stanley analyst Michael Ulz raised the firm's price target on Kyverna Therapeutics to $33 from $25 and keeps an Overweight rating on the shares. Top line data from the Phase 2 registrational study of mivocabtagene autoleucel in stiff person syndrome confirm robust, consistent activity and favorable tolerability, says the analyst, who views the results as "very positive."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KYTX
Unlock Now
Leerink
Outperform
maintain
$25 -> $32
2025-12-15
Reason
Leerink
Price Target
$25 -> $32
2025-12-15
maintain
Outperform
Reason
Leerink raised the firm's price target on Kyverna Therapeutics to $32 from $25 and keeps an Outperform rating on the shares after the company reported results from the KYSA-8 study of mivocabtagene-autoleucel. Leerink told investors that these results are transformative and represent an important advancement for stiff person syndrome patients who have no approved FDA therapies and substantial unmet medical need. The firm added that it is not surprised by strength in shares and sees an "attractive" catalyst path.
Morgan Stanley
Michael Ulz
Overweight
maintain
$20 -> $25
2025-12-04
Reason
Morgan Stanley
Michael Ulz
Price Target
$20 -> $25
2025-12-04
maintain
Overweight
Reason
Morgan Stanley analyst Michael Ulz raised the firm's price target on Kyverna Therapeutics to $25 from $20 and keeps an Overweight rating on the shares. Topline data from the registrational Phase 2 study of KYV-101 in stiff person syndrome are expected in early 2026, notes the analyst, who cites "increasing conviction in the potential of KYV-101" for the firm's higher target.
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
